Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

NIAID Data Ecosystem2026-03-09 收录

结直肠癌维持治疗

贝伐珠单抗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2206138 数据链接链接失效反馈

官方服务：

资源简介：

Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

创建时间：

2016-02-15

Supplementary Material for: Bevacizumab related gastrointestinal perforation in Hepatocellular Carcinoma patient: A Case Report

肝细胞癌

贝伐珠单抗

Introduction: Atezolizumab plus bevacizumab is widely recognized as the first-line treatment for advanced hepatocellular carcinoma (HCC). Bevacizumab, an anti-vascular endothelial growth factor (anti

DataCite Commons2025-12-18 更新80

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery

化疗神经毒性

结直肠癌维持治疗

RATIONALE: Calcium gluconate and magnesium sulfate may prevent or lessen neurotoxicity caused by oxaliplatin. It is not yet known whether calcium gluconate and magnesium sulfate are more effective tha

NIAID Data Ecosystem50

Prediction of response to bevacizumab

结直肠癌治疗响应预测

贝伐珠单抗

The patients who underwent surgery for primary lesions were examined. All patients had metastatic or recurrent CRC and received bevacizumab therapy as first line or second line treatment. Responders a

NIAID Data Ecosystem40

Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

转移性结直肠癌治疗

贝伐珠单抗

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or

NIAID Data Ecosystem60

Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer

结直肠癌维持治疗

II期临床试验

RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for resectable colorectal cancer. Treatment with current strategies, however,recurrent rate is high for stage IIIC or R

NIAID Data Ecosystem50

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

资源简介：

相关数据集